Can afamelanotide and cosyntropin be used together?

Yes, in principle. A patient with EPP taking afamelanotide for photosensitivity could still undergo cosyntropin stimulation testing if adrenal function evaluation is clinically indicated. The two peptides work on different systems and have no known pharmacological interactions. However, combined use would be rare and driven by specific clinical circumstances.

Is cosyntropin ever used as a treatment rather than a diagnostic?

Cosyntropin is occasionally used therapeutically in acute adrenal insufficiency (adrenal crisis) to rapidly boost cortisol. However, it is primarily a diagnostic agent. In acute settings, hydrocortisone is preferred. [Cosyntropin's main role remains diagnostic assessment of the HPA axis.](https://pubmed.ncbi.nlm.nih.gov/17122358)

How long does afamelanotide take to work?

Afamelanotide begins stimulating melanin production within days, with peak skin darkening typically occurring 7–10 days after implantation. Reduction in photosensitive episodes may take 1–2 weeks. Seasonal implant changes (usually summer months) are standard.

Is afamelanotide available outside specialist centres?

Afamelanotide (Scenesse) requires specialised prescribing and implantation. It is typically managed by dermatologists, genetic metabolic specialists, or porphyria centres. Availability varies by country; in the US and EU it is approved, but access programmes and specialist referral may be required.

What is the cost difference between these peptides?

Pricing varies by geography and healthcare system. Afamelanotide implants (seasonal) are typically high-cost specialty therapeutics; cosyntropin, as a generic diagnostic agent, is significantly less expensive. Insurance coverage and access programmes differ. Consult your healthcare provider for actual cost information.

Afamelanotide vs Cosyntropin: Key Differences & Uses

Afamelanotide and Cosyntropin are both FDA-approved peptides, but they work on completely different biological systems and treat different conditions. Afamelanotide is a melanocortin receptor agonist used to reduce phototoxicity in erythropoietic protoporphyria (EPP); Cosyntropin is a synthetic corticotropin analogue used diagnostically to assess adrenal function. While both are approved and have strong clinical evidence, they're not interchangeable—each addresses a specific medical need. This guide breaks down their mechanisms, evidence, regulatory paths, and when each might be appropriate.

What Is Afamelanotide?

Afamelanotide is a synthetic peptide analogue of α-melanocyte-stimulating hormone (α-MSH). It activates melanocortin-1 (MC1) receptors on melanocytes, triggering melanin production in skin cells. Afamelanotide was FDA-approved in December 2014 under the brand name Scenesse.

The primary indication is reducing phototoxicity—the painful skin reactions triggered by sunlight—in patients with erythropoietic protoporphyria (EPP), a rare genetic disorder affecting heme metabolism. By increasing melanin, afamelanotide provides a protective buffer against photosensitivity.

Clinical Evidence for Afamelanotide

A pivotal Phase 3 trial published in The Lancet demonstrated that afamelanotide reduced the number of phototoxic reactions from approximately 11 per month to fewer than 2 per month in EPP patients. The trial included 94 patients across 23 clinical investigations globally.

Key findings:

Response rate: ~75% of patients showed clinically meaningful reduction in photosensitivity episodes
Safety profile: Well-tolerated, with mild injection-site reactions being the most common adverse event
Mechanism: Works through MC1R activation, independent of systemic corticosteroids or immunosuppression

Afamelanotide carries a Category C pregnancy rating and is administered as a subcutaneous implant (usually changed every 60 days during high-sun seasons).

What Is Cosyntropin?

Cosyntropin (also called tetracosactide) is a synthetic peptide consisting of the first 24 amino acids of adrenocorticotropic hormone (ACTH). It stimulates the adrenal cortex to release cortisol and other corticosteroids.

Cosyntropin was FDA-approved in 1973 and is used primarily as a diagnostic agent—not a treatment. Physicians use cosyntropin stimulation tests to evaluate whether the hypothalamic-pituitary-adrenal (HPA) axis is functioning normally.

Common clinical scenarios:

Suspected adrenal insufficiency
Differential diagnosis of hypocortisolism (central vs. primary adrenal failure)
Post-operative assessment in patients on chronic corticosteroids

Clinical Evidence for Cosyntropin

Cosyntropin is one of the most extensively studied diagnostic peptides, with 38 registered clinical trials evaluating its diagnostic accuracy and optimal dosing.

A landmark meta-analysis in Endocrine Reviews confirmed that cosyntropin stimulation tests reliably distinguish adrenal insufficiency from normal adrenal function:

Sensitivity: >95% for detecting primary adrenal failure when paired with baseline cortisol measurement
Specificity: 90–98% depending on cortisol threshold used
Standard dose: 250 µg (both IV and IM routes are validated)

Cosyntropin is well-tolerated, with adverse events rare; mild flushing and transient hypokalemia are possible but uncommon.

Key Differences: Head-to-Head

| Feature | Afamelanotide | Cosyntropin | |---------|---------------|-------------| | Mechanism | MC1R agonist (melanin stimulation) | ACTH analogue (cortisol stimulation) | | Primary use | Therapeutic (reduce photosensitivity) | Diagnostic (assess adrenal function) | | Indication | Erythropoietic protoporphyria | Suspected adrenal insufficiency | | Administration | Subcutaneous implant (60-day duration) | IV or IM injection (single or brief series) | | Regulatory status (US) | FDA-approved | FDA-approved | | EMA status | EMA-authorised (Scenesse) | Not authorised by EMA | | Clinical trials | 23 registered | 38 registered | | Onset of action | Gradual (peak melanin increase at ~10 days) | Rapid (cortisol response within 30–60 min) | | Patient population | Rare genetic disorder (EPP) | Common (endocrine evaluation) |

Regulatory Status & Approval Timeline

Afamelanotide

The FDA granted accelerated approval in 2014 after reviewing data from over two decades of development. The EMA followed with authorisation in 2015. Both approvals recognise afamelanotide as the only approved therapy specifically addressing EPP-related photosensitivity, reflecting its orphan drug status and unmet medical need.

Cosyntropin

FDA approval dates back to the early 1970s, and it remains the gold-standard diagnostic peptide for HPA axis evaluation. Because it is used diagnostically rather than therapeutically, it has not been reviewed by the EMA in the same way; European diagnostic protocols may use equivalent ACTH analogues or different assay approaches.

When to Consider Each

Afamelanotide Is Appropriate If:

You have confirmed erythropoietic protoporphyria with documented photosensitive reactions
You have exhausted or failed to tolerate protective measures (sunscreen, protective clothing)
You have access to specialist dermatology or metabolic disease clinics
You are comfortable with subcutaneous implants and seasonal administration

Afamelanotide works best as part of a comprehensive sun-avoidance strategy, not as a standalone solution.

Cosyntropin Is Appropriate If:

You have suspected adrenal insufficiency and need diagnostic confirmation
Your physician is evaluating HPA axis dysfunction (e.g., in sepsis, post-surgical states, or endocrine workup)
You need rapid, objective laboratory confirmation before initiating steroid replacement
You are undergoing routine endocrine evaluation as part of broader diagnostic workup

Cosyntropin is a diagnostic tool, not a treatment; results guide management with other therapies (hydrocortisone, fludrocortisone, etc.).

Cross-Reference: Related Peptides

If you're exploring melanocortin agonists, melanotan II is a research compound with structural similarities to afamelanotide but remains investigational. For ACTH-related therapies, tesamorelin is an approved growth hormone–releasing hormone agonist used in HIV-related lipodystrophy, though its mechanism differs from cosyntropin.

Learn more about melanocyte function and adrenocorticotropic-hormone to deepen your understanding of how these peptides work.

Safety & Tolerability Summary

Both peptides have strong safety records in approved populations:

Afamelanotide: Injection-site reactions (erythema, induration) are most common; systemic effects are rare. Monitoring for skin changes and melanoma risk is recommended, particularly given the population's existing photosensitivity.

Cosyntropin: Adverse events are uncommon; flushing, hypokalemia, and mild hypertension may occur transiently. No cumulative toxicity with diagnostic dosing.

The Bottom Line

Afamelanotide and cosyntropin are fundamentally different tools serving different roles. Afamelanotide is a therapeutic peptide for a rare genetic skin disorder; cosyntropin is a diagnostic peptide for endocrine evaluation. Both are FDA-approved and evidence-backed, but choosing between them depends entirely on your clinical need. If you have EPP, afamelanotide may reduce photosensitive episodes. If you need adrenal function assessment, cosyntropin is the standard diagnostic agent. They are not alternatives to each other.

Afamelanotide vs Cosyntropin: A Side-by-Side Comparison